Anticancer agent 308

Anticancer agent 308 (compound 3s) potently inhibits the viability of MCF-7, MDA-MB-231, MDA-MB-468, A549, HepG2, HeLa and PC-3 cancer cells at low micromolar concentrations, while exerting minimal effects on normal NKE cells (IC₅₀ 84.15 μM), resulting in a high selectivity index^[1].
Anticancer agent 308 can induce dose-dependent cell death in MDA-MB-231 cells and reduce their colony-forming ability, while exhibiting minimal toxicity to NKE cells^[1].
Anticancer agent 308 (0.5-2 μM; 24 h) induces concentration-dependent G2/M cell cycle arrest and increases the accumulation of sub-G0 apoptotic cells in MDA-MB-231 cells; regulates the expression and activation of apoptosis-related proteins and inhibits AKT in MDA-MB-231 cells; induces concentration-dependent accumulation of ROS; induces concentration-dependent cleavage of PARP; induces concentration-dependent mitochondrial depolarization; and inhibits the migration of MDA-MB-231 cells in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.